Composition and methods for eliciting an immune response
AssigneeDuke University
InventorsJohn H. Sampson, Duane A. Mitchell
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions, methods, and kits for eliciting an immune response, in particular for eliciting an immune response to at least one antigen expressed by a cancer cell, in particular for treating and preventing cancer.
Claims20
A method for eliciting in a subject an immune response to at least one antigen expressed by a cancer cell, the method comprising:
- administering to the subject a pharmaceutically acceptable composition comprising a plurality of developmental cell antigens, or nucleic acids encoding the plurality of developmental cell antigens, wherein the pharmaceutically acceptable composition, when administered to the subject, elicits the immune response to the at least one antigen.
A pharmaceutically acceptable composition comprising a plurality of antigens expressed by a developmental cell, or nucleic acids encoding the plurality of antigens, wherein the pharmaceutically acceptable composition, when administered to a subject, elicits an immune response against at least one antigen expressed by a cancer cell.
(canceled)
A method for eliciting in a subject an immune response to at least one antigen expressed by a cancer cell, the method comprising:
- administering to the subject a composition comprising an effective amount of antigen presenting cells, T-lymphocytes, or both, wherein the antigen presenting cells and T lymphocytes have been sensitized in vitro with a sensitizing-effective amount of a plurality of antigens expressed by a developmental cell, wherein the effective amount of antigen presenting cells, T lymphocytes, or both is sufficient to elicit the immune response to the at least one antigen.
The method of claim 19, wherein the antigen presenting cells or T lymphocytes are autologous.
20-32. (canceled)
Dependencies are inferred from the claim text.